Search for a trial

An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma

The primary objective is to compare the overall response rate ORR(CR+PR), after 4 cycles, of subcutaneously (SC) administered VELCADE tointravenously (IV) administered VELCADE in patients with previouslytreated multiple myeloma.The secondary…

A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.

This study has been transitioned to CTIS with ID 2023-510110-36-00 check the CTIS register for the current data. Primary objective: To evaluate the efficacy of mepolizumab SC given every 4 weeks in participants aged 6 to 17 years with HESSecondary…